Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Jasper Therapeutics Insiders Buying or Selling?
Jasper Therapeutics (JSPR) has had 2 insider transactions in the past 90 days, all buys — insider buying is generally read as a bullish signal. The most recent was Matthew Ros, who bought 881 shares at $0.00 on July 20, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the JSPR AI Score. For government officials trading this stock, see JSPR congressional trading.
Recent Jasper Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Matthew Ros | Jul 20, 2026 | Buy | 881 | $0 | $0 |
| Patrick Crutcher | Jul 20, 2026 | Buy | 888 | $0 | $0 |
| THOMAS WIGGANS | Sep 22, 2025 | Buy | 41,000 | $0 | $0 |
| Svetlana Lucas | Sep 22, 2025 | Buy | 20,000 | $0 | $0 |
| RON MARTELL | Sep 22, 2025 | Buy | 41,000 | $0 | $0 |
| Shizuru Judith Anne | Sep 22, 2025 | Buy | 41,000 | $0 | $0 |
| Mahal Jeetinder Singh | Dec 12, 2024 | Sell | 900 | $22.11 | $20,000 |
Frequently Asked Questions: Jasper Therapeutics Insider Trading
In the past 90 days, Jasper Therapeutics insiders have made 2 buys and 0 sells. The net buying may indicate insider confidence in the company’s outlook.
The most recent sale was by Mahal Jeetinder Singh who sold 900 shares on December 12, 2024. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Mahal Jeetinder Singh has sold the most JSPR stock in the last 2 years, with a total value of $20,000.
The total value of insider transactions for Jasper Therapeutics in the last 2 years is negative, amounting to -$20,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
